US-fund­ed Phlow's first round of es­sen­tial gener­ics head­ed to chil­dren's hos­pi­tals, but they're made with for­eign APIs

US-based phar­ma man­u­fac­tur­er Phlow an­nounced ear­li­er this week that it would sup­ply es­sen­tial med­i­cines over the next quar­ter to the Chil­dren’s Hos­pi­tal Coali­tion, af­ter col­lab­o­ra­tion with the group to iden­ti­fy the med­i­cines that are at risk of be­com­ing or cur­rent­ly con­sid­ered in short sup­ply.

The gov­ern­ment-fund­ed non­prof­it has prid­ed it­self on ef­forts to shore up the sup­ply chain of ac­tive phar­ma­ceu­ti­cal in­gre­di­ents with­in the US to re­duce a re­liance on oth­er coun­tries. Rough­ly 88% of the man­u­fac­tur­ers mak­ing APIs come from over­seas, the FDA said in a 2019 re­port. And this year, the com­pa­ny will pro­vide key gener­ic med­i­cines, in­clud­ing furosemide, dex­am­etha­sone, he­parin and rocuro­ni­um for the chil­dren’s hos­pi­tals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER